Latanoprost Pharmabide

Latanoprost, the active ingredient in Latanoprost Pharmabide, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Pharmabide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Products are shipped in tamper‑evident containers and tracked through temperature‑controlled logistics when required.

Latanoprost is indicated for conditions that involve elevated intra‑ocular pressure within the glaucoma disease spectrum.

- Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: lowers eye pressure to prevent progression to glaucoma. - Pseudoexfoliative glaucoma: decreases pressure to manage this secondary open‑angle form.

Latanoprost may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Eye redness: transient hyperemia of the conjunctiva. - Increased eyelash growth: longer, thicker lashes may appear. - Iris pigmentation: gradual darkening of the iris color. - Eye irritation: burning or stinging sensation after instillation. - Blurred vision: temporary reduction in visual clarity. - Foreign body sensation: feeling of something in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract requiring medical attention. - Corneal edema: swelling of the cornea that may impair vision. - Macular edema: fluid accumulation in the central retina, potentially reducing acuity. - Vision loss: sudden decrease in vision that warrants immediate evaluation.

Before prescribing Latanoprost, clinicians should consider several safety and handling precautions.

- Monitor intra‑ocular pressure: assess response after initiation and adjust therapy as needed. - Avoid use in active ocular inflammation: may exacerbate uveitis or keratitis. - Caution in patients with herpetic eye disease: risk of reactivation. - Advise patients to discontinue contact lens wear for at least 24 hours after instillation. - Use in children only under specialist supervision: safety data are limited. - Store at room temperature: keep the bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: additive pressure‑lowering effect may cause excessive IOP reduction. - Combination with cycloplegic agents: may increase ocular absorption and enhance side‑effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: combined therapy may lead to greater IOP decrease, requiring monitoring. - Alpha‑agonist eye drops: may affect overall pressure‑lowering profile. - Systemic carbonic anhydrase inhibitors: potential for additive hypotensive effect on the eye.